RPGRIP1 Gene Therapy Program Update: June 2024

Odylia Therapeutics provides an update on the RPGRIP1 Gene Therapy program (OT-004) and hosts a Q&A session. June 2024. Odylia Therapeutics, a nonprofit biotechnology company, received a Translation Research Award for $1.5 million from the Foundation Fighting Blindness to accelerate the development of a novel gene therapy (OT-004) to treat vision loss caused by mutations in the RPGRIP1 gene.